Reacción a "The European Association for the Study of Obesity recommends semaglutide and tirzepatide as first-line treatment for obesity"

The presentation of the algorithm was a trending topic at our EASO congress in Malaga and has now been published in an official communication. The headline read: EASO, as a scientific society, gives semaglutide and tirzepatide a high ranking, positioning them at the forefront of the fight against obesity.

It's a paradigm shift or approach that focuses on fat loss rather than the goal of weight loss on a scale. It focuses on the complications of obesity when choosing treatment.

It's welcomed; I believe it's accurate and pertinent. In this new world with so many publications, it means organizing, gathering scientific evidence, compiling clinical trials to simplify the treatment for each patient, and providing treatment tailored to their chronic adipose tissue disease and its complications.